论文部分内容阅读
目的:探讨胃癌组织中表皮生长因子受体(EGFR)、人类表皮生长因子受体2(C-erbB-2)、拓扑异构酶Ⅱα(TopoⅡα)和P-糖蛋白(P-gp)的表达及其与临床病理特征的关系。方法:应用免疫组化SP法检测130例胃癌组织中EGFR、C-erbB-2、TopoⅡα和P-gp的表达情况,并结合临床病理特点进行分析。结果:EGFR、C-erbB-2、TopoⅡα和P-gp在胃癌组织中的阳性表达率依次为87.7%(114/130)、53.8%(70/130)、50%(65/130)和33.8%(44/130)。EGFR、C-erbB-2、P-gp在高、中分化胃癌中的阳性表达率明显高于低分化胃癌(P<0.05);C-erbB-2在直径<5cm的胃癌(胃体、胃窦部和幽门部,Ⅲ期和Ⅳ期胃癌)中的阳性表达率明显高于直径≥5cm的胃癌(贲门部及I期和Ⅱ期胃癌),(P<0.05);EGFR在贲门和胃体部胃癌的阳性表达率明显高于胃窦及幽门部胃癌(P<0.05);TopoⅡα在有淋巴结转移的胃癌中表达率明显低于无淋巴结转移的胃癌(P<0.05)。胃癌组织中EGFR和TopoⅡα的表达呈正相关(P<0.05)。结论:EGFR、C-erbB-2、TopoⅡα及P-gp参与胃癌的生长、侵袭和转移过程。它们的联合检测可作为判断胃癌预后、筛选高危转移患者的有效指标,同时也对胃癌的靶向药物治疗有指导意义。
Objective: To investigate the expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (C-erbB-2), topoisomerase Ⅱα (TopoⅡα) and P-glycoprotein And its relationship with clinicopathological features. Methods: The expressions of EGFR, C-erbB-2, TopoⅡα and P-gp in 130 cases of gastric carcinoma were detected by immunohistochemical SP method and analyzed with clinicopathological features. RESULTS: The positive rates of EGFR, C-erbB-2, TopoⅡα and P-gp in gastric cancer were 87.7% (114/130), 53.8% (70/130), 50% (65/130) and 33.8 % (44/130). The positive rates of EGFR, C-erbB-2 and P-gp in high and moderately differentiated gastric cancer tissues were significantly higher than those in poorly differentiated gastric cancer tissues (P <0.05). C-erbB- (P <0.05). The positive rates of EGFR expression in the gastric cardia and gastric body were significantly higher than those in the gastric cardia and stage I and II gastric cancers (P <0.05) (P <0.05). The positive rates of TopoⅡα expression in gastric cancer with lymph node metastasis were significantly lower than those without lymph node metastasis (P <0.05). The expression of EGFR and TopoⅡα in gastric cancer tissues was positively correlated (P <0.05). Conclusion: EGFR, C-erbB-2, TopoⅡα and P-gp are involved in the growth, invasion and metastasis of gastric cancer. Their combined detection can be used as an effective index to judge the prognosis of gastric cancer and screen the patients with high-risk metastasis, and also can guide the targeted drug therapy of gastric cancer.